Summary.-Twenty-four patients with advanced cancer not reacting to conventional therapy were treated with 97 courses of i.v. MER (methanol extraction residue of BCG). MER was administered by i.v. infusion over a 4-h period, twice a week, in dosages varying from 0-05 mg to 1 25 mg. The skin reactivity to 5 recall antigens was evaluated in the patients. All patients except 4 were anergic. Twelve patients had no side-effects. Anergic patients had less side-effects than ergic patients. The sideeffects recorded in the others were fever, chills, vomiting and tachycardia. The reaction subsided within 24 h after treatment and was tolerable for most patients.
reactivity, renal and hepatic functions were found. A significant increase in peripheral leucocyte count was noted in two patients and slight a increase in the remainder.
ANIMAL studies showed that i.v. BCG inhibited tumour growth after i.v. injection of tumour material (Baldwin and Pimm, 1973) and lung metastasis after surgical removal of an s.c. transplant (Morton et al., 1971) . It is not known whether the i.v. route of administration of immunotherapy is more effective than intradermal (i.d.) or s.c. routes, although theoretically it could be more effective. This stimulated interest in giving various immunostimulators such as BCG or C. parvum i.v. to cancer patients. Such Phase I studies have recently been reported, with some evidence of tumour regression (Band et al., 1975; Israel et al., 1975, Muggleton, Prince and Hilton, 1975) .
MER is the methanol extraction residue of BCG. It has the advantage over BCG of being a non-viable vaccine. Previously, we have reported that i.d. injection of MER improved skin reactivity and the lymphocyte in vitro response to various antigens (Robinson et al., 1975 (Robinson et al., , 1977 . In the present study we have evaluated tolerance to i.v. injection of MER in different dosages and its effects on skin reactivity to recall antigens in advanced cancer patients.
MATERIALS AND METHODS
Patients.-Twenty-four patients with histologically confirmed malignant neoplasms with generalized metastases were included in the study. Table I shows the diagnoses of the patients. Most patients had epithelial tumours. There were 15 females and 9 males. The age of the patients ranged between 28 and 73 years, with a median of 49 and a mean of 52 years.
The patients had been treated previously by surgery, radiotherapy and chemotherapy. MER was recommended in advanced stages of the disease, when further oncological treatment was not available. Twelve patients were on steroid therapy.
The performance status (Karnofsky scale) was higher than 7 in 3 patients, between 5 and 6 in 5 patients and less than 4 in 16 patients (Table II) transaminases), and alkaline phosphatase, Ca, P, serum urea creatinine and uric acid levels. Other X-rays and liver and bone scans were performed when indicated. After completion of each i.v. treatment, temperature, pulse and blood pressure were monitored and subjective evaluation was made. The presence or absence of chills was specifically noted each time. Temperatures above 37 6°C were considered a febrile response, and a pulse change of 20% or more defined as a tachycardic response.
RESULTS

Subjective and objective evaluation
Five patients displayed subjective improvement during and after MER therapy. One patient stopped taking analgesics and narcotics during infusions and another showed improvement in appetite and general wellbeing. Objective improvement was noticed in 2 patients. One patient suffered from (Table IV) . 'IThe highest pulse rate recorded was 140/min. The pulse regained its previous range within 24-48 h. Blood pressure Chan-ges in blood pressure were seldom encountered in patients after therapy. It was seen to decrease in only 4 patients but in no case did the systolic pressure drop below 70 mmHg. The blood pressure was found to rise transiently in 2 patients. Table IV shows the overall estimated toxicity in patients with i.v. MER treatment. Twelve patients had Ino side-effects, 8 patients were recorded as having tolerable side-effects and only 4 patients had severe side-effects. These comprised chills, fever, vomiting, nausea, muscle pains and headache. All of these patients received MER in doses of 0-5 mg. Three of the patients, as noted before, with a slightly positive skin test had more marked side-effects. The 2 patients show-ing partial remission of 5000 had febrile responses and a moderate reaction.
Overall toxicity
Cutaneous reactivity
Twenty of the patients who entered this study were anergic to 5 recall antigens. Four patients showed a weak response to the antigens tested. This was due to the advanced stage of disease, low performance status and previous radio-chemotherapy. Of the 4 patients who showed slight reactivity, 3 had febrile responses associated with chills and vomiting. Two of the 4 patients were on steroids. Of the 2 patients with a 50%/ partial response, one had a weak response to the recall antigens and the other was ergic. The skin reactivity of the patients did not change after i.v.
MER.
Laboratory examination
No major abnormalities occurred in kidney or liver function. The following changes were most probably due to progression of the disease in a patient with pancreatic tumour: serum bilirubin concentration increased from 341 to 5-1 mg and the serum transaminase concentration increased from 23 to 76 mg. In another patient, the alkaline phosphatase level fell from 7 6 to 3 7 Bessy Laury units. In most patients a slight increase in the number of leucocytes was found, and in 2 patients this was more marked. It increased from 3300 to 14,600 leucocytes per mm3 in one and from 11,000 to 22,000 leucocytes per mm3 in the other.
DISCUSSION
Immunotherapy is usually given i.d. or intratumorally. Recently, Corynebacterium parvum has been shown to be more effective when given i.v. (Band et al., 1975; Cheng et al., 1976; Fisher et al., 1976; Israel et al., 1975) . BCG has also been given i.v., but as BCG i.d. has produced fever, malaise, hepatic dysfunction and jaundice, and as there are reports of disseminated BCG infections, there are dangers with its i.v. administration (Bast et al., 1974; Mansell and Krementz, 1973; Pinsky, Hirsthaut and Oettgen, 1972; Sparks et al., 1973) . No such side-effects were described with the non-viable MER vaccine. MER has been found to be a potent immunostimulator when given i.d. (Robinson et al., 1975 (Robinson et al., , 1977 but has never been'given i.v. If MER could be administered i.v. this could be of benefit to the patients by avoiding the skin reaction at the site of MER injections. Preliminary investigations showed that mice tolerated i.v. MER injections well. The present study has shown that MER can be administered i.v. safely to patients with advanced cancer and generally poor condition. The reactions recorded were tolerable in most patients.
It remains, of course, to be proved that the i.v. route stimulates the cutaneous immune response. In the present study this was not found. We attributed this possibly to the advanced condition of the patients' disease. The dose administered to ergic patients has to be carefully monitored for possible reactions. Moertel et al. (1975) have shown objective improvement in patients with advanced gastro-intestinal cancer by i.d. MER injection. It is of interest that in the present study objective improvement was observed in 2 patients.
It is our purpose to continue with MER i.v. therapy in patients with disease not reactive to the conventional treatments, in order to see whether further objective improvement can be obtained.
